News and Announcements
OncoSil Receives $2.3m R&D Tax Incentive Refund
- Published September 27, 2016 3:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th September 2016, ASX Announcement
OncoSil Medical Limited (ASX:OSL) (OncoSil Medical or the Company) a late stage medical company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce it has received a cash refund from the Australian Taxation Office of $2.3 million following the lodgement of the 2015/16 financial year tax return. The cash is rebate is related to the expenditure on eligible Australian and international R&D activities conducted during the 2015/16 financial year.
The Company has approximately $14.0m in cash and cash equivalents with the receipt of these funds.
To view the full announcement, please click on the button below.